KRSA Stock: Price, Earnings History and SEC Filings
Korsana Biosciences, Inc. (KRSA) last traded at $30.14, down 0.26% on the latest session and down 5.8% over the past month. In its most recent reported quarter (Dec 2025) earnings per share were $-1.33 against an analyst estimate of $-2.66, a beat of 50.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
KRSA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Dec 2025 | Mar 30, 2026 | $-1.33 | $-2.66 | +50.00% |
KRSA beat the analyst EPS estimate in 1 of its last 1 reported quarters. Source: Nasdaq.
KRSA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $2M | -$4M | – | -170.1% | $-1.11 |
| 2024 | $2M | -$3M | – | -152.8% | $-1.21 |
| 2023 | $0 | -$5M | – | – | $-2.25 |
| 2022 | $297000 | -$44M | -$41M | -14841.1% | $-20.28 |
| 2021 | $4M | -$52M | -$37M | -1310.2% | $-1.32 |
| 2020 | $2M | -$78M | -$74M | -3388.6% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for KRSA
- DEF 14A · Oct 15, 2026
- 8-K · Sep 11, 2026Material agreement, Acquisition or disposal completed, Results of operations
- 8-K · Aug 27, 2026Shareholder vote, Other events, Financial statements and exhibits
- 8-K · Aug 25, 2026Other events
- 10-Q · Aug 4, 2026
- 424B3 · Jul 24, 2026
- 10-Q · May 12, 2026
- 8-K · Apr 1, 2026Material agreement, Officer or director change, Regulation FD disclosure
- 10-K · Mar 30, 2026
- 8-K · Feb 17, 2026Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
KRSA insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
KRSA news
- Korsana Biosciences, Inc. Common Stock (KRSA) EarningsOct 28, 2026 · fxempire.com
- KRSA - Korsana Biosciences, Inc.Oct 28, 2026 · seekingalpha.com
- Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?Oct 27, 2026 · finance.yahoo.com
- Korsana Biosciences Director Michael Higgins Announces Sale of 1,107 Shares via Form 144 FilingOct 22, 2026 · kalkinemedia.com
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. (KRSA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in MA. Its fiscal year ends in December.